Smithkline Beecham Corporation

Other

The University of Texas System

University of Pennsylvania

Sb Laboratoires Pharmaceutiques

Masashi Yanagisawa

Derk J. Bergsma

David P. Brooks

Miklos Gellai

Shelagh Wilson

Derk J Bergsma

Catherine E Ellis

Usman Shabon

Ganesh Madhusudan Sathe

Nabil A Elshourbagy

Jeffrey L Mooney

Henry M Sarau

Wendy S Halsey

Steven M Ruben

Robert S Ames

James J Foley

Joyce Y Mao

Wendy S Fuetterer

Dwight Edward Stambolian

Craig A Rosen

Xiaotong Li

Winnie Chan

Nassirah Khandoudi

David P Brooks

Peter R Young

Stephanie Van Horn

Yuan Zhu

John Timothy Lonsdale

Conrad Gerald Chapman

Sherin Salaheldin Abdel-Meguid

Rajeev Aurora

Mary E Brawner

Robert N Willette

Anne Romanic Arnold

Jon Chambers

Jeffrey S Culp

Jonathan K Chambers

George D Rose

Nambi V Aiyar

Megan E Depiera

Masahi Yanigasawa

Chandrika Saidapet-Kumar

Da-Yuan Wang

Kamal Al-Barazanji

Stephen A Douglas

Bernard Gout

Stephanie F Guerrera

Preston Hensley

Phillipe Robert

Polypeptides of HFGAN72 receptor ligands and polynucleotides encoding the polypeptides are provided. Methods of using these polypeptides to diagnose diseases relating to the under- or over-expression of HFGAN72 receptor ligands are also provided. In addition, methods of identifying agonists or antagonists of the interaction of HFGAN72 receptor ligands with the HFGAN72 receptor are provided. Methods of treatment by administering the identified agonists or antagonists to patients in need thereof are further disclosed.

Ligands of the neuropeptide receptor HFGAN72

Screening methods using ligands of the neutropeptide receptor HFGAN72

Urotensin-II Receptor (UTB-R) polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing Urotensin-II Receptor (UTB-R) polypeptides and polynucleotides in therapy, and diagnostic assays for such.

Polynucleotides encoding mouse urotensin-II Receptor (UTB-R)

Human EDG-1c polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Human EDG-1c is identified as a selective receptor for sphingosine-1-phosphate (&ldquo;S-1-P&rdquo;) and for di-hydro S-1-P. Also diclsosed are methods for discovering agonists and antagonists of the interaction between S-1-P and di-hydro S-1-P and their cellular receptor, human EDG-1c, which may have utility in the treatment of several human diseases and disorders.

Polynucleotide sequences of human EDG-1c

Mouse CC-CKR5 polypeptides and DNA (RNA) encoding such mouse CC-CKR5 and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such mouse CC-CKR5 in the development of gene knockout mice for use as a model for human immunodeficiency virus.

Mouse CC-CKR5 receptor polypeptide

The present invention relates to 11cby, in particular 11cby polypeptides and 11cby polynucleotides, recombinant materials and methods for their production. In another aspect, the invention relates to methods for using such polypeptides and polynucleotides, including the treatment of bacterial, fungal, protozoan and viral infections, particularly infection caused by HIV-1 or HIV-2; pain; cancers; diabetes; obesity; feeding and drinking abnormalities, such as anorexia and bulimia; asthma; Parkinson's disease; both acute and congestive heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; allergies; benign prostatic hypertrophy and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia or severe mental retardation, and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, hereinafter referred to as &ldquo;the Diseases&rdquo;, among others. In a still further aspect, the invention relates to diagnostic and prognostic assays for detecting diseases associated with inappropriate 11cby activity or levels. A method of performing genetic association studies for searching a disease susceptibility and/or drug response genes comprising using polymorphic markers in 11cby polynucleotides.

11 cby genomic sequence

Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72

HTLAR33 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also, disclosed are methods for utilizing HTLAR33 polypeptides and polynucleotides in therapy, and diagnostic assays for such.

YAK-1 related serine/threonine protein kinase-HTLAR33

Fatty Acid Synthase polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilising Fatty Acid Synthase polypeptides and polynucleotides in therapy, and diagnostic assays for such.

Human FAS

Human G-Protein Coupled Receptor HNFDS78 polypeptides and DNA (RNA) encoding such G-Protein Coupled Receptor HNFDS78 and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such G-Protein Coupled Receptor HNFDS78 for the treatment of diseases, such as, atherosclerosis, inflammatory disease, and infectious disease. Antagonists against such G-Protein Coupled Receptor HNFDS78 and their use as a therapeutic to treat disease are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides. Also disclosed are diagnostic assays for detecting mutations in the polynucleotides encoding G-protein coupled receptors and for detecting altered levels of the polypeptide in a host.

Nucleic acids encoding the G-protein coupled receptor HNFDS78

HNFDY20 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HNFDY20 polypeptides and polynucleotides in the design of protocols for the treatment of infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, among others and diagnostic assays for such conditions.

cDNA clone HNFDY20 that encodes a novel human 7-transmembrane receptor

EF-7 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing EF-7 polypeptides and polynucleotides in therapy, and diagnostic assays for such.

Cytokine family member EF-7

The present invention provides a method for high throughput cloning of full length cDNA sequences using a pooling strategy. This method uses a plurality of clone arrays prepared from cDNA libraries which have been preferably enriched for 5 &prime; mRNA sequences and size fractionated into several discrete ranges (sub-libraries). These arrays are used to rapidly identify the full length cDNA sequence for a DNA segment of interest.

Methods for rapid cloning for full length cDNAs using a pooling strategy

Novel 7TM receptor (H2CAA71) polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing Novel 7TM receptor (H2CAA71) polypeptides and polynucleotides in the design of protocols for the treatment of infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, among others and diagnostic assays for such conditions.

7TM receptor (H2CAA71)

Human neurotensin type 2 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing human neurotensin type 2 polypeptides and polynucleotides in the design of protocols for the treatment of infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, among others and diagnostic assays for such conditions.

Human neurotensin receptor type 2 and splice variants thereof

Growing community of inventors

Berwyn, PA, United States of America

Derk J Bergsma